Clinical Research Directory
Browse clinical research sites, groups, and studies.
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
Sponsor: University of Alabama at Birmingham
Summary
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this imaging study. Individuals participating in this AV-1451-PET/MRI study will also be enrolled in an ongoing \[C-11\]PiB-PET/MRI study (IRB-300001005, IND-138128), and their amyloid, tau and cognitive statuses will be compared in terms of race and vascular risk factors.
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2020-07-08
Completion Date
2028-07
Last Updated
2025-12-11
Healthy Volunteers
Yes
Conditions
Interventions
[F-18]AV-1451-PET
All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
Locations (1)
UAB
Birmingham, Alabama, United States